DK1720866T3 - Fremgangsmåde - Google Patents

Fremgangsmåde

Info

Publication number
DK1720866T3
DK1720866T3 DK04804455.6T DK04804455T DK1720866T3 DK 1720866 T3 DK1720866 T3 DK 1720866T3 DK 04804455 T DK04804455 T DK 04804455T DK 1720866 T3 DK1720866 T3 DK 1720866T3
Authority
DK
Denmark
Prior art keywords
course
action
Prior art date
Application number
DK04804455.6T
Other languages
English (en)
Inventor
Mathias Berwe
Joachim Rehse
Dirk Grotjohann
Christian Thomas
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to DE102004002044A priority Critical patent/DE102004002044A1/de
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Priority to PCT/EP2004/014870 priority patent/WO2005068456A1/de
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34716548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1720866(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application granted granted Critical
Publication of DK1720866T3 publication Critical patent/DK1720866T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
DK04804455.6T 2004-01-15 2004-12-31 Fremgangsmåde DK1720866T3 (da)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102004002044A DE102004002044A1 (de) 2004-01-15 2004-01-15 Herstellverfahren
PCT/EP2004/014870 WO2005068456A1 (de) 2004-01-15 2004-12-31 Herstellverfahren

Publications (1)

Publication Number Publication Date
DK1720866T3 true DK1720866T3 (da) 2011-11-21

Family

ID=34716548

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04804455.6T DK1720866T3 (da) 2004-01-15 2004-12-31 Fremgangsmåde

Country Status (33)

Country Link
US (1) US7351823B2 (da)
EP (1) EP1720866B1 (da)
JP (2) JP5311742B2 (da)
KR (1) KR20130004257A (da)
CN (1) CN1906191B (da)
AR (1) AR047389A1 (da)
AT (1) AT518856T (da)
AU (1) AU2004313694B2 (da)
BR (1) BRPI0418405B1 (da)
CA (1) CA2553237C (da)
CY (1) CY1112565T1 (da)
DE (1) DE102004002044A1 (da)
DK (1) DK1720866T3 (da)
EC (1) ECSP066703A (da)
ES (1) ES2369140T3 (da)
GT (1) GT200400277A (da)
HK (1) HK1103722A1 (da)
HN (1) HN2005000016A (da)
HR (1) HRP20110796T1 (da)
IL (1) IL176767A (da)
MA (1) MA28290A1 (da)
MY (1) MY138944A (da)
NO (1) NO335553B1 (da)
NZ (1) NZ548506A (da)
PE (1) PE20050763A1 (da)
PL (1) PL1720866T3 (da)
PT (1) PT1720866E (da)
RU (1) RU2383540C2 (da)
SI (1) SI1720866T1 (da)
TW (1) TWI340137B (da)
UY (1) UY28718A1 (da)
WO (1) WO2005068456A1 (da)
ZA (1) ZA200605747B (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047564A1 (de) 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
AU2006299126B2 (en) * 2005-10-04 2012-06-28 Bayer Intellectual Property Gmbh Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
WO2009018807A1 (de) * 2007-08-06 2009-02-12 Schebo Biotech Ag Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
DE102008028071A1 (de) 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
US8435989B2 (en) * 2009-04-28 2013-05-07 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
US8309547B2 (en) * 2009-04-28 2012-11-13 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
EA031064B1 (ru) 2009-07-31 2018-11-30 КРКА, д.д., НОВО МЕСТО Способы кристаллизации ривароксабана
CN102822167A (zh) * 2010-01-04 2012-12-12 埃南蒂亚有限公司 用于制备利伐沙班的方法及其中间体
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
EP2388260A1 (de) 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN107021932A (zh) * 2010-06-29 2017-08-08 欧美嘉股份有限公司 制备5‑左旋‑氨甲基‑3‑芳基‑2‑恶唑烷酮类的方法
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) * 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs) * 2010-09-30 2012-04-11 Farmak, A. S. Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
WO2012051692A1 (en) 2010-10-18 2012-04-26 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
UA114601C2 (uk) * 2011-05-06 2017-07-10 Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
ES2395304B1 (es) 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
CN102250076A (zh) * 2011-05-27 2011-11-23 横店集团家园化工有限公司 一种利伐沙班中间体及利伐沙班的制备方法
CN102827154B (zh) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
EP2753619A2 (en) 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
WO2013053739A1 (en) 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Process for preparing factor xa inhibitors
WO2013121436A2 (en) * 2012-02-06 2013-08-22 Megafine Pharma (P) Ltd A process for preparation of rivaroxaban and intermediates thereof
CZ2012114A3 (cs) * 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh) 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
CN102659756A (zh) * 2012-04-01 2012-09-12 南京哈柏医药科技有限公司 5-氯-2-酰氯噻吩的合成方法
JP2015514114A (ja) 2012-04-06 2015-05-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation リバーロキサバンを調製するためのプロセス
CN102757424B (zh) * 2012-07-09 2014-10-15 云南大学 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) * 2012-07-24 2015-04-08 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法
WO2014020458A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of rivaroxaban
CN102786516B (zh) * 2012-08-21 2014-10-01 湖南师范大学 一种利伐沙班的合成方法
CN103833724A (zh) * 2012-11-20 2014-06-04 上海医药工业研究院 一种5-氯噻吩-2-甲酰氯的制备方法
CN103864771A (zh) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 一种利伐沙班的制备方法
CN103864772A (zh) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 一种利伐沙班及其中间体的制备方法
PL2935255T3 (pl) 2012-12-21 2018-01-31 Farma Grs D O O Sposób wytwarzania rywaroksabanu
PL2895176T3 (pl) 2012-12-26 2017-05-31 Wanbury Limited Związek pośredni Rywaroksabanu i jego wytwarzanie
IN2012MU03359A (da) 2012-12-26 2015-06-26 Wanbury Ltd
IN2013MU01113A (da) 2013-03-25 2015-06-19 Glenmark Generics Ltd
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
CN103275061A (zh) * 2013-06-04 2013-09-04 上海同昌生物医药科技有限公司 一种生产5-氯噻吩-2-羧酸的方法
CN103351385A (zh) * 2013-06-28 2013-10-16 浙江燎原药业有限公司 一种利伐沙班中间体的制备方法
CN103709116B (zh) * 2013-12-10 2015-09-23 四川大学 一种4-(4-烷氧羰氨基)苯基-3-吗啉酮的制备方法
CN103724336B (zh) * 2013-12-24 2015-10-21 悦康药业集团有限公司 一种新型抗凝血药物的合成方法
IN2014MU00072A (da) 2014-01-08 2015-08-21 Wockhardt Ltd
IN2014CH00290A (da) 2014-01-23 2015-08-14 Symed Labs Ltd
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
WO2015188787A1 (en) * 2014-06-14 2015-12-17 Sunshine Lake Pharma Co., Ltd. Method for preparing oxazolidinone compound and intermediates thereof
CN104086539A (zh) * 2014-07-17 2014-10-08 天津炜捷制药有限公司 一种利伐沙班的制备方法
CN104211693B (zh) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 一种利伐沙班晶型及其制备方法与用途
CN104211694A (zh) * 2014-08-14 2014-12-17 广东东阳光药业有限公司 一种改进的制备Xa因子抑制剂的方法
EP3186246A1 (en) * 2014-08-25 2017-07-05 Cipla Limited Process for the preparation of rivaroxaban
WO2016062828A1 (en) 2014-10-22 2016-04-28 Zaklady Farmaceutyczne Polpharma S.A Process for preparing a polymorph of rivaroxaban
CN104807934B (zh) * 2015-04-30 2017-01-18 成都百裕制药股份有限公司 异吲哚二酮类化合物的正相高效液相色谱检测方法
CN105130976A (zh) * 2015-08-26 2015-12-09 浙江车头制药股份有限公司 一种利伐沙班中间体的合成方法
CN105440028B (zh) * 2015-12-07 2018-03-13 石家庄康贺威药业有限公司 一种利伐沙班化合物及其制备方法
CN106008490B (zh) * 2016-01-11 2019-01-04 南京生命能科技开发有限公司 一种利伐沙班的新晶体及其制备方法
CN106977507A (zh) * 2017-04-21 2017-07-25 上海华源医药科技发展有限公司 一种利伐沙班的制备方法
WO2019163731A1 (ja) * 2018-02-26 2019-08-29 住友化学株式会社 オキサゾリジノン化合物の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid

Also Published As

Publication number Publication date
IL176767D0 (en) 2006-10-31
ES2369140T3 (es) 2011-11-25
KR20130004257A (ko) 2013-01-09
RU2383540C2 (ru) 2010-03-10
NO20063677L (no) 2006-10-11
CY1112565T1 (xx) 2016-02-10
HN2005000016A (es) 2009-06-01
CN1906191B (zh) 2010-05-26
TWI340137B (en) 2011-04-11
US7351823B2 (en) 2008-04-01
WO2005068456A1 (de) 2005-07-28
CA2553237C (en) 2012-04-17
ECSP066703A (es) 2006-10-31
BRPI0418405A (pt) 2007-05-15
PL1720866T3 (pl) 2012-01-31
SI1720866T1 (sl) 2012-01-31
CA2553237A1 (en) 2005-07-28
NO335553B1 (no) 2014-12-29
CN1906191A (zh) 2007-01-31
BRPI0418405B1 (pt) 2018-03-13
DE102004002044A1 (de) 2005-08-04
JP2012097106A (ja) 2012-05-24
PT1720866E (pt) 2011-10-12
MA28290A1 (fr) 2006-11-01
US20050182055A1 (en) 2005-08-18
NZ548506A (en) 2009-06-26
AU2004313694B2 (en) 2011-06-02
GT200400277A (es) 2005-08-18
HK1103722A1 (en) 2011-01-14
UY28718A1 (es) 2005-08-31
RU2006129341A (ru) 2008-02-20
AU2004313694A1 (en) 2005-07-28
AR047389A1 (es) 2006-01-18
TW200604195A (en) 2006-02-01
EP1720866A1 (de) 2006-11-15
JP5311742B2 (ja) 2013-10-09
PE20050763A1 (es) 2005-12-02
AT518856T (de) 2011-08-15
ZA200605747B (en) 2007-10-31
EP1720866B1 (de) 2011-08-03
IL176767A (en) 2011-04-28
MY138944A (en) 2009-08-28
JP2007517816A (ja) 2007-07-05
HRP20110796T1 (xx) 2011-12-31

Similar Documents

Publication Publication Date Title
DK1833840T3 (da) Micromirs
DK1587343T3 (da) Höreapparat
DK1744635T3 (da) Stöbeform
DK1737504T3 (da) Silikonehudpåføringsgel
DK1809382T3 (da) Tokomponenttandblegningssammensætninger
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1786344T3 (da) Cementleveringsnål
DK1720859T3 (da) Chemokinreceptorantagonister
DK1737596T3 (da) Skæreværktöj
AT381906T (de) Trokar
DE602005014923D1 (de) Teilchenbestrahlungssystem
NL300749I2 (nl) Secukinumab
DE602005011516D1 (de) Nähfadenankereinführungssystem
DE602005011251D1 (de) Zettenvorrichtung
AT447853T (de) Enyzmgranulat
AT415112T (de) Abschminkapplikator
AT360450T (de) Sicherheitsdauerverweilnadel
DE602004025621D1 (de) Stentreduziersystem
AT455498T (de) Zenteseinstrument
AT538176T (de) Polymilchsäureharzzusammensetzung
DE502005005035D1 (de) Wischblatt
AT526869T (de) Hydratationsmonitor
DE502005009257D1 (de) Wischblatt
BRPI0508788A (pt) tiadiazolidinonas como inibidores de sqg - 3
AT442115T (de) Unterkiefervorschiebeorthese